Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study

Eur Urol. 2020 Jun;77(6):759-760. doi: 10.1016/j.eururo.2020.02.026. Epub 2020 Feb 27.

¹ Department of Oncology, University of Oxford, Oxford, UK.
² Department of Oncology, University of Oxford, Oxford, UK; Department of Oncology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
³ Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: richard.bryant@nds.ox.ac.uk.

No abstract available

Publication types